Travel technology company Sabre (NASDAQ:SABR) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 4% year on year to $714.7 million. Its non-GAAP loss of $0.08 per share was 22% above analysts’ consensus estimates.
Game engine maker Unity (NYSE:U) reported Q4 CY2024 results beating Wall Street’s revenue expectations, but sales fell by 25% year on year to $457.1 million. On the other hand, next quarter’s revenue guidance of $410 million was less impressive, coming in 5.6% below analysts’ estimates. Its GAAP loss of $0.30 per share was 18.6% above analysts’ consensus estimates.
The convertible note offering is expected to close tomorrow.
Shares of Alibaba Group listed in the U.S. are jumping in premarket trading Thursday after the Chinese tech and e-commerce giant reported quarterly results that beat estimates.
Vehicle manufacturer Shyft (NASDAQ:SHYF) fell short of the market’s revenue expectations in Q4 CY2024, with sales flat year on year at $201.4 million. On the other hand, the company’s outlook for the full year was close to analysts’ estimates with revenue guided to $920 million at the midpoint. Its non-GAAP profit of $0.15 per share was 18.4% above analysts’ consensus estimates.
Walmart-backed Indian fintech firm PhonePe is beginning preparatory steps for a public listing on the country's stock exchanges, the company said on Thursday. "PhonePe's strong top-line and bottom-line growth across its diverse business portfolio, as detailed in its FY23-24 annual report, makes this a suitable time to prepare for a public listing," the company said in a statement. The Indian stock market saw a significant upswing for much of 2024, with many companies launching their IPOs, but a downturn since October has weighed on investor sentiment.
Aerospace and defense company Leonardo DRS (NASDAQ:DRS) reported Q4 CY2024 results topping the market’s revenue expectations, with sales up 5.9% year on year to $981 million. The company’s full-year revenue guidance of $3.48 billion at the midpoint came in 1.6% above analysts’ estimates. Its non-GAAP profit of $0.38 per share was 7.6% above analysts’ consensus estimates.
Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) met Wall Street’s revenue expectations in Q4 CY2024, but sales were flat year on year at $167.5 million. The company’s outlook for the full year was close to analysts’ estimates with revenue guided to $697.5 million at the midpoint. Its non-GAAP profit of $0.44 per share was 7.9% above analysts’ consensus estimates.
Healthcare company Baxter International (NYSE:BAX) beat Wall Street’s revenue expectations in Q4 CY2024, but sales were flat year on year at $2.75 billion. On the other hand, next quarter’s revenue guidance of $2.58 billion was less impressive, coming in 1.4% below analysts’ estimates. Its non-GAAP profit of $1.89 per share was significantly above analysts’ consensus estimates.
